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Abstract
Background: The saphenous vein remains the most frequently used conduit for
coronary artery bypass grafting, despite reported unsatisfactory long‐term patency
rates. Understanding the pathophysiology of vein graft failure and attempting to
improve its longevity has been a significant area of research for more than three
decades. This article aims to review the current understanding of the pathophy-
siology and potential new intervention strategies.
Methods: A search of three databases: MEDLINE, Web of Science, and Cochrane
Library, was undertaken for the terms “pathophysiology,” “prevention,” and “treat-
ment” plus the term “vein graft failure.”
Results: Saphenous graft failure is commonly the consequence of four different
pathophysiological mechanisms, early acute thrombosis, vascular inflammation, in-
timal hyperplasia, and late accelerated atherosclerosis. Different methods have been
proposed to inhibit or attenuate these pathological processes including modified
surgical technique, topical pretreatment, external graft support, and postoperative
pharmacological interventions. Once graft failure occurs, the available treatments
are either surgical reintervention, angioplasty, or conservative medical management
reserved for patients not eligible for either procedure.
Conclusion: Despite the extensive amount of research performed, the pathophy-
siology of saphenous vein graft is still not completely understood. Surgical and
pharmacological interventions have improved early patency and different strategies
for prevention seem to offer some hope in improving long‐term patency.
K E YWORD S
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1 | INTRODUCTION
Coronary artery bypass grafting (CABG) remains the gold standard
treatment for severe coronary artery disease, especially for patients
with diabetes and low ejection fraction.1 The most frequently used
conduits for CABG are the left internal thoracic artery (LITA) and the
long saphenous vein (LSV). While the LITA has been shown to have
an excellent long‐term patency rate, it is limited by its length and
therefore it is not generally suitable for multiple grafts.2,3 The LSV,
on the other hand, is readily available in greater lengths to construct
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more than one graft and can be harvested at the same time as the
LITA. For these reasons, the LSV remains one of the most commonly
used conduits for CABG.3 Other conduits not extensively used are
the radial artery and the right internal thoracic artery.1
Despite its extensive use, the LSV graft suffers short‐term failure
and has a low long‐term patency rate resulting in lower long‐term
survival and event‐free survival compared with arterial grafts.2,4
Over the years, there has been increased interest in under-
standing the pathophysiology involved in the development of vein
grafts disease as although many therapeutics have been suggested,
none has been successful enough to make them widely adopted. This
is in part related to our limited understanding of the complex pa-
thological processes involved in the development of the disease
starting from vascular inflammation (VA) to superimposed athero-
sclerosis, the cross‐talk between the different cells forming the LSV
and the influence of the circulating cells and other molecules. The
overall process is thought to be marked by complex interactions
between several factors owned to either the patient or the technique
which will ultimately impact the pathophysiology of the disease,
making its study challenging.
2 | METHODS
Original research articles and reviews were selected as they related
to the pathophysiology, prevention, and treatment of SV graft failure.
A literature search was performed using MEDLINE, Web of Science,
and Cochrane Library. The search was focused on human, transla-
tional, in vitro, and animal studies.
3 | RESULTS
3.1 | Pathophysiology of LSV graft failure
The pathophysiology of LSV graft failure has been described as
driven by four interconnected and related processes: early acute
thrombosis (AT), VA, intimal hyperplasia (IH), and late accelerated
atherosclerosis.5,6
3.1.1 | Acute thrombosis
It is widely accepted that AT is responsible for the majority of early
vein graft failures.5,7 This process starts from the harvesting of the
LSV, where surgical injury combined with hypoxia caused by damage
to the vasa vasorum, oxidative stress, wall distention, and acute
elevation of shear stress can lead to endothelial dysfunction and
activation and make it switch to a prothrombotic state, or even de‐
endothelialize the vessel exposing the extracellular matrix (ECM) to
the blood in the lumen.6,8 This results in a loss of balance between
antithrombotic and prothrombotic systems in favor of the latter
with a marked reduction of nitric oxide (NO), prostacyclin (PGI2),
thrombomodulin, and heparin‐like substances in injured endothelium
associated with increased expression of adhesion molecules and
the sensitivity of the vascular smooth muscle cells (VSMC) to
vasoconstrictors.6,9 Furthermore, there is simultaneous activation of
the coagulation cascade resulting in platelet activation and ad-
herence to the de‐endothelialized areas with the generation of dif-
ferent pro‐coagulation factors such as thromboxane A2, fibrinogen,
fibronectin, thrombospondin, von Willebrand factor, platelet factor
IV, and b‐thromboglobulin.6,7,9‐11 These processes combined can
culminate in 3% to 12% early graft occlusions.7
It has been described that the endothelial lining of the grafts can
recover after this initial process, although, as described below, the
new endothelium can be dysfunctional.10,12
3.1.2 | Intimal hyperplasia
IH is a chronic disease where the VSMCs in the medial layer switch
from a quiescent state to a synthetic proliferative, resulting in mi-
gration to the intimal layer where they proliferate causing further
thickening of the intimal.8,13 The function of both VSMCs and en-
dothelial cells (ECs) is linked by their physical and paracrine inter-
actions, which controls vascular tone, cell proliferation and response
to inflammation.14 In a healthy state the interaction between ECs and
VSMCs keeps the VSMCs in a quiescent state; via EC‐derived
homeostatic molecules like NO which help regulate the tone of the
medial layer and suppress VSMC phenotypic switching to synthetic
cells.14 Local inflammation and endothelial injury cause the ECs to
switch to a prothrombotic state and, therefore, this interaction is
disrupted.10 This, can be further enhanced by the release of cyto-
kines like interleukin‐6 (IL‐6), IL‐8, and thromboxane A2 and growth
factors like platelet‐derived growth factor and fibroblast growth
factor from activated platelets and leukocytes contributing to VSMC
phenotypic switching to synthetic phenotype and proliferation.10,15
Also, it is known that both ECs and VSMCs secrete ECM proteins,
and this may be a way of indirect communication, which induces
VSMC phenotypic switching and proliferation.14 ECs may also induce
VSMCs proliferation via microRNAs. For example, increased levels of
endothelial‐derived miR‐126 resulted in higher VSMC turnover
(proliferation and apoptosis).16 On the other hand, ECs microRNAs
miR‐143/145 have been associated with decrease IH possibly
through downregulation of VSMC phenotypic switching mechanism;
while miR‐126 seems to contribute to the formation of IH since its
depletion in mice resulted in IH suppression.17 However, these stu-
dies relate specifically to IH and not in the context of LSV graft.
After the initial denudation, new ECs can be seen as early as the
first week after surgery in experimental models, however, after the
endothelium is restored the process of IH does not reverse, this is
thought to be in part due to the increase of shear stress on the wall
which makes the new endothelium dysfunctional and partly due to
the now chronic localized inflammatory response.5,11,18
Some studies on VSMCs have identified the importance in the
development of IH, of Kruppel‐like factor 4 (KLF4) and Kruppel‐like
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factor 5 (KLF5), both protein‐coding genes. KLF4 acts as a down-
regulator of VSMCs contractile markers such as smooth muscle
α‐actin, SM22α, and smooth muscle myosin heavy chain, thus
switching the cell to a synthetic state. However, KLF4 may serve as an
athero‐protective factor, its overexpression in ECs induces the upre-
gulation of anti‐inflammatory and antithrombotic factors.19 KLF5 has
been seen to increase in response to vascular injury and athero-
sclerotic lesions.19 KLF5 may activate VSMCs to switch, migrate and
proliferate as is preferentially expressed in de‐differentiated VSMCs. A
study also found an association between KLF5 positive VSMCs and a
higher risk of graft restenosis in rabbits.19,20
Other important factors in the development of IH that have been
studied are p38 mitogen‐activated protein kinase (p38), and nuclear
factor kappa‐light‐chain‐enhancer of activated B cells both have been
evidenced to induce VSMC proliferation in vitro using models of
cultured VSMCs and on coculture models of VSMCs and ECs.21‐23
The development of IH is, a complex process in which the VSMCs
and the ECs play a crucial role, but the entire process is not yet
completely understood, and by expanding our comprehension of this
process we may find new therapeutic targets to reduce the rate of
LSV graft failure.
3.1.3 | Accelerated atherosclerosis
Atherosclerotic disease progresses much rapidly in LSV grafts as
compared to native arteries, as its lipolysis is slower and suffers from
accelerated lipid uptake.24 Compared to native atherosclerotic pla-
ques, the LSV plaque is more highly populated with foam cells and
other inflammatory cells, including multinucleated giant cells. It has
been detected that some of these cells may originate from venous
VSMCs rather than from circulating cells, making IH an important
contributor to the speed and severity of atherosclerosis in vein
grafts.24
Like the native artery atherosclerosis, the vein graft athero-
sclerosis can suffer plaque rupture and AT, which has been described
in necropsy samples.25 However, the vein graft atherosclerosis tends
to be diffuse, concentric, and friable with a poorly developed or ab-
sent fibrous cap and little evidence of calcification, making it more
prone to rupture than native artery atherosclerotic plaques.6,18,26,27
3.1.4 | The role of inflammation
At any time during the development of the previous three mechan-
isms of LSV graft failure, there can coexist a certain degree of
localized acute or chronic inflammation, which exacerbates the pa-
thophysiological stage of the graft failure. During the initial phase of
this process the exposure of the ECM to the lumen of the vessel in an
area of de‐endothelialisation recruits leukocytes and platelets. These
cells infiltrate the intima, this process will alternate between acute
and chronic with more or less leukocyte activation.10 IH is enhanced
by growth factors and cytokines IL‐1, IL‐6, and tumoral necrosis
factor‐alpha released by inflammatory cells. In a later stage, mono-
cytes infiltrate the IH layer and differentiate into macrophages as is
developing into an atherosclerotic plaque and develop into foam
cells as they would on the artery's atherosclerosis due to uptake of
lipid, but the localized chronic inflammatory changes make this pro-
cess happen faster than in native arteries. Intimal macrophages
secrete matrix metalloproteinases which lead to ECM and cell‐to‐cell
contact cleavage further inducing VSMCs migration into the intima
and proliferation. The presence of VSMCs within the intimal layer,
triggers further inflammation, attracting additional macrophages into
the IH layer, thus accelerating atherosclerosis (see above).18
During this process of inflammation damage to perivascular fat
will release cytokines and recruit lymphatic cells in the vessel's
adventitia which will, in turn, secrete proinflammatory cytokines,
disruption of perivascular fat also reduces the bioavailability of NO
which acts as a regulator of vascular tone and signals the VSMCs to
stay in a contractile state.10,18
3.2 | Prevention of LSV failure
The quest for modifiable factors that influence graft failure has
occurred for more than three decades. Some of the following are
methods that may reduce the incidence of graft failure.
3.2.1 | Reducing atherosclerosis risk factors
Atherosclerosis associated risk factors are still present in the patient
after CABG, some of which have been directly associated with poor
prognosis of the LSV grafts.6
• Smoking: Multiple studies have identified the role of smoking habit
in the development of both long and short‐term LSV graft disease
and inferior survival after CABG.7,28,29
• Dyslipidaemia: Evidence points towards hyperlipidaemia as one of
the main risk factors in the development of vein graft disease;
cholesterol levels higher than 240mg/dL have shown a significant
increase in the rate of LSV graft obstruction, similarly as found in
native coronary disease with the relation between LDL cholesterol
and HDL cholesterol is as important as the total serum cholesterol.
The elevation of triglycerides in the serum has also been related to
late vein graft failure. Furthermore, there is a strong association
between dyslipidaemia and long‐term morbidity and mortality
after CABG. Aggressive treatment and prevention of hyperlipi-
daemia has been associated with better long‐term outcomes.30‐32
• Hypertension: Despite its role in systemic atherosclerosis, studies
looking at hypertension as a risk factor for LSV failure have found
no such association.6
• Diabetes mellitus (DM): There is conflicting evidence regarding the
influence of DM on vein graft disease. Some studies have found
that poorly controlled DM is associated with worse survival after
CABG, while others found no significant difference in the rate of
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LSV graft occlusion.30,33 No prospective study has explicitly looked
at DM as a risk factor for LSV graft failure, and several laboratory
studies have shown that DM impairs some of the vasodilator
mechanisms, suggesting a role in graft disease.30,33
3.2.2 | Surgical technique
There is compelling evidence that a technique or surgical strategy
affects LSV graft failure.
• Endoscopic vs Open LSV harvesting: Minimizing surgical trauma
and improvement in patient's quality of life was the driving for the
development of endoscopic vein harvesting. However, there is now
concern over this technique due to lower long‐term patency rates
of LSV grafts retrieved endoscopically.34‐36
• Distention: There is a large body of evidence that harvesting and
subsequent distention of the LSV at more than 150mmHg causes
endothelial denudation exposing the ECM to the lumen, and in-
creases rates of long‐term graft failure.18,37,38
• Harvesting, skeletonized vs “no‐touch” LSV harvesting: Preserving
the vein adventitia and the perivascular fat let to the development
of the “no‐touch” technique, which consists of harvesting the LSV
with its perivascular fat and ligating the tributaries at least one
centimeter away from the vein. This technique associated with
nonabove‐arterial pressure distention has demonstrated in some
studies to provide substantially better long‐term outcomes in
terms of vein graft patency. However, it has the disadvantage of
being associated with a higher incidence of graft site complications
in the early postoperative period.38‐42
• Vein preservation media: The choice of preservation media during
storage of the LSV prior to its use has been associated with in-
creased concentration of free oxygen radicals and ischemia in all
layers of the vein.43 On this subject, ex‐vivo studies have shown a
benefit in using the patient's heparinized blood, but this benefit
has not been able to be demonstrated in clinical practice.43 How-
ever, recent studies have demonstrated that a pH buffer in either
crystalloid or blood media has provided a significant clinical
benefit.43,44
• Technical aspects: Anastomotic technique is thought to be crucial
for graft longevity, with poor technique and excessive surgical
trauma associated with early vein graft failure. Accurate graft
length is critical, both too short and too long grafts suffer from
worse outcomes. There is evidence that graft longevity is depen-
dent on the target vessel and its capacity to provide a good runoff
flow. Advocates of the good runoff theory suggest that sequential
anastomoses achieve a better runoff and lesser peripheral re-
sistance to flow and therefore, improved long‐term patency.41,45‐48
While some evidence supports this statement a recent paper
found worse rates of LSV graft failure with sequential anasto-
moses.41,45‐48
• Flow measurement: Transit time flow measurement (TTFM) may
provide the surgeon with a tool for assessing both anastomosis
quality and distal runoff while still in the operating theater; the
current guidelines are that it should be considered. However, there
are discrepancies in what values are considered acceptable and
studies looking at this technique as a predictor for graft failure
tend to use different values which are sometimes arbitrary.
Despite these limitations, TTFM has shown to be useful in de-
termining technical graft problems as is highly specific when a graft
has a negative flow or high resistance, which can be caused by
problems in the anastomosis.48‐51
3.2.3 | External graft support
External stenting has been proposed to reduce the rate of IH on vein
grafts, by imposing LSV graft symmetry, more laminar flow and the
subsequent reduction of shear stress, and also by providing a pro-
tective environment for the formation of new adventitia. However,
despite promising results in animal models,52 early clinical trials have
shown conflicting results such as a higher failure rate on right‐sided
grafts.53 Further trials will be needed before its application in clinical
practice.52‐56
3.2.4 | Topical pretreatment
Storage of the LSV before its use provides a window of opportunity
for topical treatments.18,57
Gene therapy of the graft before implantation, have shown en-
couraging results in experimental animal models but contrasting
results in the clinical context.9,58‐60 There has been a success in
ex‐vivo models with TIMP‐3 gene therapy and a clinical trial has been
proposed.61
3.2.5 | Pharmacological therapy
• Aspirin: Several prospective randomized trials have looked at the
influence of aspirin vs placebo after CABG and demonstrated an
increase in graft patency in patients receiving aspirin.62,63 Current
trials recommend that aspirin therapy should be started as soon as
possible after the operation as it has shown that if it started after
the third day after surgery, it provides no benefit.62 Consequently,
its implementation in the first‐day postoperation showed a sig-
nificant reduction of both early and late graft failure. Another
important consideration is that it has been demonstrated that part
of the population appears to be nonresponsive to aspirin and does
not experience the same benefits as responding to patients.2,62,63
Current indications suggest starting aspirin as early as 6 hours
after surgery and continuing high dose aspirin for at least a year,
also if tolerated low dose aspirin is indicated after that for sec-
ondary prevention of atherosclerosis.1
• Dual antiplatelet: Recent guidelines recommend dual antiplatelet
therapy with clopidogrel and aspirin for patients undergoing
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CABG. Recent studies have shown a decrease in cardiovascular
mortality in patients with dual antiplatelet therapy; however, it is
still unclear whether different antiplatelets therapies combined
with aspirin provide different outcomes.35,41,64 There is a need for
trials that evaluate the efficacy of different antiplatelet agents
when compared to each other.
• Statins: Hyperlipidaemia is a major contributor to LSV graft
disease, and statin therapy has a beneficial effect on event‐free
survival after CABG.32 The American Heart Association re-
commends the use of statins after CABG in the absence of contra‐
indications.32,65‐67
3.3 | Treatment after LSV failure
When vein graft failure results in clinical events or symptoms, it will
require treatment. Deciding the appropriate therapy after LSV graft
failure is often problematic and should be a decision taken by a
multidisciplinary heart team.7 The treatment options are usually
percutaneous coronary intervention (PCI) and repeat CABG; both
have significantly increased risks as compared to first‐time inter-
vention. Therefore, some patients will be deferred to medical man-
agement instead. 7
3.3.1 | Vein graft angioplasty
PCI after vein graft failure accounts for 5% to 10% of all PCIs per-
formed in the United States in a year,68 the procedure is technically
challenging, especially if treating early graft failure, the risk of distal
embolization is high, and some authors suggest the use of distal
embolic protection devices. Regarding the choice of the stent, recent
studies suggest that drug‐eluting stents may offer an advantage over
bare‐metal stents. Long‐term results are better with PCI than with
medical treatment alone but are far from ideal and are indeed worse
than outcomes of patients without vein graft failure.7,69
3.3.2 | Reoperation
Repeat CABG may be an option for patients with LSV graft disease.
However, is with a significantly higher risk of mortality and morbidity,
which is increased in cases when one or more of the grafts are patent,
or for of lack available conduits. Comparison between long‐term
outcomes between reoperation and PCI is difficult as there is a sub-
stantial selection bias, but similarly to PCI long‐term outcomes after
reoperation are worse than those of patients with no graft failure. 70
3.3.3 | Medical management
Although both PCI and reintervention offer better long‐term out-
comes than medical therapy sometimes the initial elevated risk may
preclude patients from receiving either intervention, in those cases
patients will be managed with a combination of medical therapy and
control of risk factors to achieve at least symptomatic control.7,71
4 | CONCLUSIONS
Vein graft failure is a multifactorial process embedded in an already
complex disease, atherosclerosis. Recent studies have helped further
our understanding of the pathophysiology of this condition and have
already yielded advancements in its secondary prevention; there is
still to be seen the impact of these advancements in the reduction of
long‐term vein graft failure.
The clinical significance of LSV graft failure remains debated.34
The main limitation to research on this subject is the lack of a
standardized classification of graft failure as some authors con-
sider flow limitation and occlusion as comparable and others think
this should be analyzed separately.36 This is also important
when researching factors that affect LSV graft patency as there is
much discrepancy in the literature in the definition of patency
and of what constitutes early‐, mid‐, and long‐term failure; this
makes a comparison between studies particularly difficult in this
subject.
Another problem in ascertaining the real clinical consequences of
LSV failure is the wide variety of techniques used on bypass grafting,
which have demonstrated to influence the rate of failure and long‐
term survival and symptoms, an example will be a study that de-
monstrated that LSV failure impaired long‐term survival when it was
grafted in the left anterior descending artery.72 This may no longer
be valid as currently, most surgeons prefer to use the LITA for this
coronary graft.
In the variety of studies that have investigated the clinical impact
of LSV failure, most have found an increased need for reintervention
as compared with patients who underwent CABG but did not have
LSV failure, on the long‐term survival. however, studies have shown
opposing results with some showing a decrease on survival with graft
failure and others no difference.34,36
Research in this area is still required as the saphenous vein re-
mains an essential conduit for CABG and by further our under-
standing of the mechanism of its failure, we may discover even more
therapeutic approaches to both the treatment and the prevention of
this condition.
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